Immunotherapy
Steering committee:
Gunnar Kvalheim, leader
Svein Dueland
Gustav Gaudernack
Arne Kolstad
Olav Engebråten
Aim:
The hospital has an extensive research program on different types of in-house developed cancer vaccines and antibody based immunotherapy approaches. The aim of these projects is to:
Gunnar Kvalheim, leader
Svein Dueland
Gustav Gaudernack
Arne Kolstad
Olav Engebråten
Aim:
The hospital has an extensive research program on different types of in-house developed cancer vaccines and antibody based immunotherapy approaches. The aim of these projects is to:
- Develop new cancer vaccines and immuno-gene-therapy approaches.
- Study T-cell responses following different immunotherapy approaches and identify and characterise novel cancer antigens recognised by patients immune system ( antibodies and T-cells).
- Initiate clinical vaccine trials on synthetic tumour specific peptides and gene modified dendrite cells
- Perform clinical trials employing systemic treatment with tumour associated monoclonal antibodies alone or conjugated with radioisotopes or toxins.